Real-world efficacy, safety, and drug retention of anakinra and canakinumab in paediatric colchicine-resistant familial Mediterranean fever: Insights from a single-centre cohort
Modern Rheumatology · 31.08.2026 · 36 (5) · 817-825
DOI: 10.1093/mr/roag015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Rheumatology, online erschienen am 21.02.2026. Verfasst von Şengül Çağlayan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Rheumatology, Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey. Hauptthemen laut MEDLINE: Familial Mediterranean Fever, Interleukin 1 Receptor Antagonist Protein, Antibodies, Monoclonal, Humanized, Antirheumatic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Background
This study evaluated the efficacy, safety, and drug retention of anakinra and canakinumab in paediatric patients with colchicine-resistant familial Mediterranean fever (cr-FMF) within a real-world cohort.
Methods
This retrospective cohort study was conducted from June 2016 to April 2024, including 86 patients diagnosed with cr-FMF. Clinical and laboratory parameters, including attack frequency, C-reactive protein, serum amyloid A, and autoinflammatory disease activity index (AIDAI) scores, were recorded at baseline and during follow-up.
Results
A total of 86 patients (50 females, 36 males) were included in the study. All carried exon 10 MEFV mutations, with 69 patients (80.2%) having the M694V/M694V genotype. Anakinra was initiated in 36 patients (41.9%), and canakinumab in 50 patients (58.1%). The median treatment duration was significantly longer for canakinumab (48 months) compared to anakinra (7 months) (P < .001). Both treatments significantly reduced attack frequency, AIDAI scores, C-reactive protein, and serum amyloid A levels compared to baseline (P < .001). While the reduction in attack frequency was comparable between the groups, patients treated with canakinumab achieved significantly lower mean AIDAI scores at 12 months compared to the anakinra group (P = .021). Anakinra provided a more rapid onset of symptom control but was commonly discontinued due to injection site reactions (44.4%). Canakinumab was associated with sustained long-term disease control with fewer local side effects. However, rare serious events, including acute myeloid leukaemia and inflammatory bowel disease, were observed, though causality with treatment could not be established.
Conclusions
In this paediatric cohort of cr-FMF patients, both anakinra and canakinumab were effective in reducing disease activity and inflammation. Anakinra offered rapid symptom relief but had frequent injection site reactions. Canakinumab provided sustained control with fewer local side effects but required monitoring for rare complications. Key points
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Rheumatology, Umraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
- Department of Pediatric Rheumatology, Antalya Training and Research Hospital, University of Health Sciences, Antalya, Turkey.
- Department of Pediatric Rheumatology, Şehit Prof. Dr İlhan Varank Sancaktepe Training and Research Hospital, University of Health Sciences, Istanbul, Turkey.
ORCID-Profile: Şengül Çağlayan, Kadir Ulu, Eray Tunce, Betül Sözeri
Zitieren
APA
Çağlayan, Ş., Coşkuner, T., Ulu, K., Yiğit, R. E., Türkmen, Ş., Baykal, G. Ö., Tunce, E., Uçar, S. A., & Sözeri, B. (2026). Real-world efficacy, safety, and drug retention of anakinra and canakinumab in paediatric colchicine-resistant familial Mediterranean fever: Insights from a single-centre cohort. Modern Rheumatology, 36(5), 817-825. https://doi.org/10.1093/mr/roag015
Vancouver
Çağlayan Ş, Coşkuner T, Ulu K, Yiğit RE, Türkmen Ş, Baykal GÖ, et al. Real-world efficacy, safety, and drug retention of anakinra and canakinumab in paediatric colchicine-resistant familial Mediterranean fever: Insights from a single-centre cohort. Modern Rheumatology. 2026;36(5):817-825. doi:10.1093/mr/roag015
BibTeX
@article{alayan2026,
author = {Çağlayan, Şengül and Coşkuner, Taner and Ulu, Kadir and Yiğit, Ramazan Emre and Türkmen, Şeyma and Baykal, Gülcan Özomay and Tunce, Eray and Uçar, Sıla Atamyıldız and Sözeri, Betül},
title = {Real-world efficacy, safety, and drug retention of anakinra and canakinumab in paediatric colchicine-resistant familial Mediterranean fever: Insights from a single-centre cohort},
journal = {Modern Rheumatology},
year = {2026},
volume = {36},
number = {5},
pages = {817--825},
doi = {10.1093/mr/roag015}
}
EUVIMED